Effects of BCG-treatment on urinary bladder cancer with focus on nitric oxide by Thiel, Tomas
Thesis for doctoral degree (Ph.D.)
2019
Effects of BCG-treatment on Urinary 
bladder cancer, with focus on nitric oxide
Tomas Thiel
From MMK (Molecular medicine and Surgery)
Karolinska Institutet, Stockholm, Sweden
EFFECTS OF BCG-TREATMENT 
ON URINARY BLADDER CANCER, 
WITH FOCUS ON NITRIC OXIDE
Tomas Thiel
Stockholm 2019
 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Arkitektkopia AB, 2019 
© Tomas Thiel tomas.thiel@ki.se, 2019 
ISBN 978-91-7831-501-9
Principal Supervisor:
Ass. Prof. Petra de Verdier 
Karolinska Institutet 
Department of Laboratory Medicine 
Division of Clinical Chemistry
Co-supervisors:
Prof. M.D. Peter Wiklund  
Karolinska Institutet 
Department of Molecular  
Medicine and Surgery (MMK)
Ph.D. M.D. Lotta Renström Koskela 
Karolinska Institutet 
Department of Molecular  
Medicine and Surgery
Opponent:
Prof. M.D. Ralph Peeker 
Göteborg Universitet 
Institute of Clinical Sciences
Examination Board:
Prof. M.D. Per-Uno Malmström 
Uppsala Universitet 
Department of Surgical Sciences
Ass. Prof. M.D. Magnus Hellström 
Karolinska Institutet 
Department of Molecular  
Medicine and Surgery
Ass. Prof. Mattias Carlström 
Karolinska Institutet 
Department of Physiology  
And Pharmacology 
Effects of BCG-treatment on Urinary 
bladder cancer, with focus on nitric oxide
THESIS FOR DOCTORAL DEGREE (Ph.D.)
The thesis will be defended at Birkeaulan, Karolinska Universitetssjuhuset 
Huddinge
Friday, June 14, 2019 at 9:00 a.m.
By
Tomas Thiel

Vissa dagar bär, man lyfter,  
svävar omkring med sin lycka. 
Färgerna vilar lättjefullt 
på sina föremål. 
Ljuden skojar vänligt med öronen. 
Fötterna är varma, huvudet svalt. 
Tankarna åker skridskor på blankis.  
De genomför alla tänkbara figurer 
utan att förlora balansen. 
Man kan sitta i lugn och ro, 
nysta ihop slingorna av sitt 
ihoprafsade liv.
Andra dagar, 
andra dagar ska vi inte tala om.
Tommy Olofsson ”Om härliga dagar” 1976
To Fanny and Lova

ABSTRACT
Intravesical Bacillus Calmette-Guérin is used as a single agent or adjuvant therapy 
in the treatment of non-muscle invasive bladder cancer. In spite being one of the 
most efficient immunological treatments in cancer, BCG for bladder cancer is 
afflicted with a number of unsolved problems. One third of the patients do not 
respond, and BCG treatment may delay alternative curative therapies. The exact 
mechanism of action of BCG on bladder cancer is still in question. Further research 
and investigation is required to understand how to identify the non-responders, how 
to optimize treatments and decrease side effects, and ultimately which patients are 
most suitable for treatment and will have the most favourable results.
In this thesis, we have examined the long-term effects and efficacy of BCG in 
bladder cancer, and in line with previous research in our group, investigated pos-
sible roles of nitric oxide in the BCG reaction. Our aim was to deepen the under-
standing of the BCG-reaction, and ultimately to identify a predictive marker for 
BCG-treatment of bladder cancer. We investigated the long-term efficacy of BCG 
at reducing recurrence, progression and cancer specific mortality (CSM); and more 
specifically if NO played a part in these processes
The third paper of this thesis showed that BCG reduced the long-term risk of recur-
rence (HR 0.40 p<0.0001) and progression (HR 0.52 p=0.038) in high-risk NMIBC 
in a fixed cohort followed for 15 years. Concerning progression, the risk reduction 
was only statistically significant in patients without concomitant CIS. For CSM 
there was no statistically significant risk reduction. The other two studies suggest 
a role for NO in BCG treatment of bladder cancer. Firstly, we have identified pos-
sible predictive markers in BCG treatment. In the same cohort as above, promoter 
and intragenic polymorphisms in NOS2 and NOS3 were associated with altered 
outcomes after BCG treatment. Secondly, we have confirmed earlier findings that 
NO concentration is increased in the bladder during the induction course of BCG 
treatment and that macrophages stimulated with BCG express both NOS2 and NO. 
We have shown in vitro that urothelial bladder cancer cells express NOS2 and NO 
and, perhaps more importantly that this reaction and BCG induced cytotoxicity 
depend upon activated macrophages. Interestingly, macrophage dependent BCG 
induced cytotoxicity was independent of nitric oxide.
Future implications of these findings require further research, most importantly 
to verify our findings about NOS polymorphisms and BCG efficacy in a larger 
cohort, but also to investigate the association between NOS polymorphisms and 
functional outcome (NOS expression and NO formation) in bladder cancer.
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11 INTRODUCTION
1.1 Urinary Bladder cancer
1.1.1 Epidemiology
In 2018 2800 persons in Sweden were diagnosed with bladder cancer, making it 
the 6th most common malignancy in total and 2nd to prostate cancer in the urinary 
tract. The prevalence of bladder cancer the same year was 24500 persons. The large 
difference between incidence and prevalence is due to the high proportion of low 
malignant superficial tumors that result in a high morbidity but low cancer-related 
mortality (CSM). The relative 5-year survival rate in 2015 was 70 %, and every 
year there are approximately 700 bladder cancer deaths in Sweden1. Incidence and 
mortality rates vary considerably by country with the highest rate recorded for men 
in Spain (age standardized incidence (ASI) 27/100000). Globally in 2018 bladder 
cancer was the 6th most common cancer among males with a ASI of 10/1000002. 
1.1.2 Pathophysiology
As in most cancers, the main risk factor for bladder cancer is age. Environment 
appears to contribute more than genetic factors, and smoking is estimated to 
contribute to one half of all bladder cancer cases3. The incidence differs between 
men and women (3:1). Chemical agents such as aromatic amines and polycyclic 
hydrocarbons are associated with bladder cancer, and 20 % of all bladder cancer 
is considered to be associated with exposure to carcinogens at work4. Chronic 
inflammation from urolithiasis, recurrent infection or an in-dwelling catheter is 
also considered to cause bladder cancer. Although not as important in bladder 
cancer as in other urological malignancies, hereditary factors do contribute to an 
increased risk. First grade relatives have a doubled risk and twin studies indicate 
that 1/3 of the risk of bladder cancer is due to hereditary factors5,6. Among genes 
identified, are FGFR3 (superficial tumors) and NAT2 and GSTM1 (resistance to 
tobacco smoke)7,8. Lynch syndrome is also associated with bladder cancer and is 
estimated to cause <5 % of all cases of bladder cancer9. 
1.1.3 Histopathology and staging
Histologically, urothelial carcinoma is the most common type of bladder cancer in 
Sweden, outnumbering adenocarcinoma and squamous cell carcinoma, by a rate 
of 19:1. The distinction between non-muscle invasive bladder cancer (NMIBC) 
and muscle invasive bladder cancer (MIBC) is important in urothelial carcinoma. 
NMIBC is classified as Ta, T1 and cancer-in-situ (CIS). Pathological grade, accord-
ing to the WHO grading system from 1973, ranges from G1 to G3. It is the most 
common type and accounts for 75 % of all newly diagnosed tumors10. Prognosis 
for NMIBC with a 5-year cancer specific survival (CSS) rate, ranging from >99% 
2(TaG1) to 70% (T1), is substantially better compared to MIBC, which have a 
5-year CSS rate of less than 35 %11. Prognosis also differs in superficial cancer 
cases, with the risk of recurrence and progression depending on factors such as age, 
T-stage, malignancy grade, tumor size and number, and presence of concomitant 
CIS11,12. From these parameters, superficial tumors with a particular high risk of 
progression have been identified. High risk NMIBC consists of T1G1-T1G3, CIS 
and TaG3 tumors. T1 and CIS tumors are considered to be particularly malignant, 
with an almost 50% 5-year risk of progression13,14. 
Figure 1. Stages in bladder cancer TNM classification.
1.1.4 Treatment
Transurethral resection of bladder tumor (TUR-BT) is the initial standard pro-
cedure for urothelial carcinoma, being a mandatory diagnostic tool for all stages 
but also radical treatment for the majority of cases of NMIBC. Treatment options 
for muscle invasive tumors are radical cystectomy or radiotherapy with the addi-
tion of neoadjuvant or adjuvant systemic chemotherapy. In addition to TUR-BT, 
adjuvant treatment is also recommended in NMIBC. In low and intermediate risk 
NMIBC, mutamycin intravesical chemotherapy decreases the risk of recurrence10. 
In high risk NMIBC this treatment has no or little effect. The recommendation for 
these cancers is intravesical treatment with bacillus Calmette and Guerin (BCG), 
which is considered to decrease the risk for recurrence and delay progression10. 
The success rate of intravesical BCG as compared to other immunomodulating 
cancer treatment is high, with 2/3 of cases experiencing a 5-year recurrence-free 
interval15,16. For non- responders however, BCG treatment delays more radical 
treatment and procedures and thereby results in an increased risk of metastatic 
3disease and Cancer specific mortality (CSM)17. For NMIBC of particular high 
risk, such as extensive T1 with concomitant CIS, radical cystectomy without prior 
intravesical treatment is recommended.
1.2 BCG in urinary bladder cancer
1.2.1 Background
At the Pasteur institute in the 1910s, the researchers Albert Calmette and Camille 
Guérin developed the BCG vaccine from attenuated Mycobacterium Bovis18. In 
1929, the American biostatistician Raymond Pearle, showed that cancer was less 
frequent in autopsied tuberculosis patients than in the population as a whole19. This 
discovery resulted in extensive research on BCG as cancer therapy. From animal 
studies in the 1960’s and 70’s, Zbar et al identified three prerequisites for BCG 
to be effective in cancer treatment; viable BCG, close contact between BCG and 
target cancer cells and an intact immune system20,21. The risk of adverse events and 
contagion made BCG difficult to use in most cancers. However the presence of 
tight junctions in the bladder mucosa made NMIBC a good candidate. Intravesical 
BCG as developed and introduced by Morales in the 1970’s proved to be an effi-
cacious and safe treatment for patients with NMIBC and is now an established 
standard treatment for high-risk superficial bladder tumors12,22.
1.2.2 BCG immunotherapy in bladder cancer
1.2.2.1 Treatment 
BCG is given either as monotherapy against CIS or as additional treatment after 
TUR-BT in exophytic T1- and Ta-tumors. It is recommended for all inter mediate- 
and high-risk NMIBCs and consists of weekly instillations over a 6-week induction 
course. Thereafter, maintenance therapy is recommended with monthly instil-
lations for 1 to 3 years, in cases of CIS and high-risk NMIBC12. Local adverse 
events such as bladder pain and dysuria are common (30 %), while severe adverse 
events such as reactive and systemic inflammation are rare (<5 %)23. While it is 
well established that intravesical BCG reduces the number of recurrent tumors in 
high-risk NMIBC, with a complete response rate as high as 80 % in primary CIS, 
there is uncertainty whether BCG-treatment prevents or delays muscle invasion, 
progression to metastases, or if it decreases cancer-specific mortality (CSM)24,25. 
1.2.2.2 Mechanism of action
Despite extensive research, the exact mechanisms through which BCG mediates 
its anti-tumor effect remain unclear. The reaction is classified as a type 4 hyper-
sensitivity reaction, and the response is thus mediated by cells rather than anti-
bodies. The initial reaction is local and non-specific and is initiated by the binding 
of BCG to fibronectin and the uptake of the bacteria by tumor cells, urothelial cells 
4and anti-gene presenting cells (APC) in the bladder wall. The following reaction 
includes an activation of the innate and specific immune system as indicated both 
in vitro and in vivo by the increased concentration of cytokines and chemokines 
in the urine and the appearance of immune cells in the infected tissue26,27. Several 
lines of evidence suggest both direct effector-target cell contact and an active role 
of immune cells28.
Figure 2. Mechanism of action – BCG (Adopted from Redelman-Sidi 2014).
Natural killer cells (NK) are involved in the non-specific immune response against 
tumor cells. A subtype of these cells, BCG-activated killer cells (BAK), has been 
identified in the bladder wall of BCG-treated patients. In Knock Out (KO)-mice 
without BAK-cells the effect of BCG is reduced29. 
Specific immune cells such as CD4-positive and CD8-positive lymphocytes are 
crucial for the effect of BCG. In the absence of these cell types, the anti-tumoral 
effect of BCG is substantially reduced30. The cytokine profile with a preponderance 
of interferon-gamma (IFNγ), interleukin-2 (IL-2), IL-12 and IL-8 over IL-10 and 
IL-4 as well as the accumulation of cytotoxic T-cells, indicate a Th1 rather than 
a Th2 response31. In KO-mice without production of IFNγ or IL-12, the BCG 
reaction is absent32. 
Mycobacteria such as BCG are intracellular microbes. Normally the internalization 
of mycobacteria is limited to APCs such as dendritic cells and macrophages. The 
5major histocompatibility complex (MHC)-mediated presentation of mycobacterial 
antigen on the cell surface results in an activation of a specific immune response 
involving both auxiliary and cytotoxic T-lymphocytes whose reactivity has been 
directed towards mycobacteria-infected cells. Activation leads to the elimination 
of both intracellular mycobacteria and of infected cells. Tumor cells seem to be 
more vulnerable to mycobacteria than normal urothelium. In vitro mutations in the 
phosphatase and tensin homolog (PTEN) gene and rat sarcoma gene (RAS) resulted 
in an increased uptake of mycobacteria in tumor cells and an increased expression 
of MHC II molecules on their surface28,33. Increased MHC II expression on tumor 
cells has been associated with a higher response rate in BCG treated patients34.
In vitro, BCG stimulation induces macrophage cytotoxicity against bladder  cancer 
cells35-37 and increased cytokines of macrophage origin have been detected in the 
urine of BCG stimulated patients, as well as macrophages within the bladder wall27,38. 
Despite these findings, no in vivo studies have confirmed a positive role for macro-
phages in BCG treatment of bladder cancer. Instead, high numbers of tumor infil-
trating macrophages (TAM) are associated with a reduced recurrence free survival 
interval after BCG treatment39.
1.2.2.3 Predictive markers
Despite being the most effective intravesical therapy for NMIBC, recurrence 
and progression rates after intravesical BCG treatment range from 32-45 % and 
10-13 % respectively12. Features such as tumor grade and stage, prior recurrence 
rate and tumor multiplicity are currently the best predictors for BCG response40. 
Aside from these there are no reliable predictive markers in clinical use for the early 
identification of non-responders to BCG-treatment. General tuberculosis immune 
status as indicated by a pre-BCG purified protein derivative (PPD) skin test, cor-
relate with treatment outcomes as well as the level of urine cytokines IL-2 and 
Il-8 during treatment. However, interindividual variation and low specificity makes 
these less suitable as predictive markers 41,42. The immunologic milieu surrounding 
the tumor environment such as the presence in the tumor of Th1 immune cells or 
NOS2 prior to BCG treatment has been associated with increased recurrence43,44. 
A Th2- polarized milieu nevertheless, with a high ratio of GATA-3+ and T-bet+ 
lymphocytes was found to correlate with a favorable response to BCG treatment44. 
The role of macrophages is complicated due to their dual roles in tumor immu-
nological response, however, a high number of CD68+ tumor associated macro-
phages before BCG treatment, was associated with a higher recurrence rate after 
cessation of the treatment45. Attention has also been drawn to host related genetic 
factors and single nucleotide polymorphisms in IL-4, IL-6 and tumor necrosis fac-
tor alfa (TNFα) genes have been associated with outcome after BCG treatment46. 
Epigenetic factors also appear to influence the post-BCG outcome. These include 
the methylation profiles of the genes coding for G/T binding protein (GTBP) and 
6thrombospondin (THBS), suppressor genes involved in DNA mismatch repair 
and neovascularization47. These findings are potentially significant and therefore 
warrant further research and evaluation.
1.3 Nitric oxide
1.3.1 Background
Nitric oxide (NO) was identified as an important biologically active molecule in 
the 1980’s and Ignarro, Furchgott and Murad were awarded the Nobel Prize in 
1998 for its role in vasodilatation. Nitrite and nitrate formation by macrophages 
after BCG infection had also been observed by this time. Hibbs et al showed that 
formation of NO is associated with activation of macrophages while Moncada 
et al and Ignarro et al independently identified that endothelial derived relaxing 
factor (EDRF), the factor associated with vasodilation, was identical to NO48-50. 
1.3.2 Formation
1.3.2.1 Enzymes
The enzyme that catalyzes the reaction from which arginine is oxidized to citrul-
line and NO was identified in 1989 and named nitric oxide synthase (NOS). Three 
isoforms were determined, neuronal(n)NOS/NOS1, inducible(i)NOS/NOS2 and 
endothelial(e)lNOS/NOS3. NOS1 and NOS3 are calcium dependent and produce 
NO transiently, at a low concentration, whereas activation of NOS2 leads to a 
sustainable production of NO at a high concentration independent of calcium. 
The co-factors in this reaction are nicotine amide adenine dinucleotide phosphate 
(NAPDH), calmodulin, tetrahydrobiopterin, flavin adenine dinucleotide (FAD), 
flavin mononucleotide (FMN) and heme51. 
Figure 3. Nitric oxide formation by NOS enzymes.
71.3.2.2 Activation and regulation of NOS2
While NOS1 and NOS3 are constitutively expressed and regulated by calcium 
fluxes, NOS2 is very scarcely expressed in resting cells. NOS2 needs induction 
by an intrinsic or extrinsic factor to be formed and activated. Most of the active 
NOS2 is located in the cytosol or in the mitochondriae52. The activity of NOS2 
is both species- and cell dependent and the expression is regulated primarily by 
transcriptional and translational mechanisms. The pathways involved vary between 
cell types, but activation of the transcription factors NFκB and STAT1 seem to be 
essential for most cell types53. In murine studies, NOS2 expression is induced by 
cytokines and lipopolysaccharides (LPS). In humans, however, the mechanism is 
more complex and involves also epigenetic alterations such as methylation and 
histone modifications54. Mycobacteria induce NOS2 by activation of toll-like 
receptors in the macrophage cell wall and in mice this appears to be a mechanism 
for bacterial elimination55. In humans however, the regulation of NOS2 includes 
a posttranscriptional modification where mRNA is stabilized under the influence 
of micro (mi)RNA56. Transforming Growth factor beta (TGFβ) is a decisive factor 
herein but also in translation and degradation of NOS257. Function and formation 
of NOS2 depends on the micro milieu, in the modifying action by NO itself. In 
a feed-back mechanism NO inhibits transcription by S-Nitrosylation of factors 
such as NFκB, but also later on in translation by inhibiting NOS2 dimerization, 
and thereby transition into its active state58. Another factor related to the micro 
milieu is hypoxia. Stabilization of hypoxia inducible factor (HIF)-1α, has been 
shown to be paralleled by an increased NOS2 activity in activated macrophages59. 
Substrate availability is also of importance. Arg-1 (arginase in cytosol), present 
both in macrophages and tumor cells, cleaves arginine into urea and ornithine, 
thereby causing a lack of substrate, which impedes the activity of NOS2. M2 
macrophages, associated with low NOS2 activity are rich in arginase, a factor that 
might explain their immunomodulating features60. 
1.3.3 Effects
1.3.3.1 Chemical and physical properties
NO is a small, uncharged molecule that, unlike almost all other molecules,  contains 
an unpaired electron. This accounts for NOs chemical and physical properties and 
its ambiguous physiological and pathophysiological role in biology. Unpaired elec-
trons are unstable and therefore all reactions that involve NO aim to stabilize the 
unpaired electron. This can happen in two ways; by pairing with another unpaired 
electron, or to share one electron with a transition metal. As a result, NO reacts 
either with other radicals, such as molecular oxygen (O2) or superoxide (O2-), 
or with transition metals, most importantly iron (Fe) in the heme molecule. The 
former reaction ultimately results in oxidation of the nucleophilic components of 
nucleic and amino acids, in particular the thiols in cysteine and phenol rings in 
8tyrosine and amines in DNA. This results in reconfiguration and altered function 
of proteins and nucleic acids containing these compounds. In the latter reaction 
where one metal ion, e.g. Fe2+, turns into another, e.g. Fe3+, the state of the metal-
containing bio logically active substance, such as heme in guanylate cyclase, is 
changed61. Unlike other known biological messengers, NO moves almost only by 
free diffusion62. This movement is not directional and is determined by concentration 
gradients. Being small and uncharged, NO has a high diffusion constant and  diffuses 
from a higher to a lower concentration at an average speed of one cell length/ms 
(cell radius 4-15 μm, total 150-300 μm)62. As an almost non-polar  molecule, NO is 
slightly soluble in water while it is highly soluble (x10) in hydrophobic solvents62. 
As such, NO does not require specialized membrane carriers, easily crosses double-
layered membranes and is not confined to the cellular compartment where it is 
produced63. The half-life of NO has been estimated to be 5-15 s62. Due to its high 
diffusion constant, and in spite of its relatively short half-life, NO acts rather in a 
paracrine rather than in an autocrine manner62,64.
Figure 4. Nitric oxide molecule with 1 unpaired electron.
1.3.3.2 Biological properties
The effect of NO is highly dependent on its concentration. At a high concentration, 
(μM) following activation of NOS2, NO is cytotoxic, and is involved in the defense 
and deletion of pathogens and tumors56,65. At lower concentrations (nM) nitric oxide 
acts as a signaling molecule regulating smooth muscle relaxation and blood flow, 
neurotransmission and cell proliferation, survival and resistance. The biological 
effect at a particular concentration is not fixed, and depends also on the micromilieu 
and the affected cell type. Phosphorylation of soluble guanolyl cyclase (sGC) to 
cyclic guanosine monophosphate (cGMP), the reaction that results in smooth muscle 
relaxation and vasodilation, only requires some 10nM. At a concentration of 100nM, 
NO promotes angiogenesis and proliferation, while concentrations above 500nM 
result in formation of the highly reactive and cytotoxic compound peroxynitrite, 
which leads to reduced cell proliferation and cell death. The concentration of NO 
depends not only on the availability of substrates and the formation and activation 
of NOS, but also on the distance between the target and NO-forming cell and the 
rate of production and consumption of the molecule in vivo66,67. 
9Figure 5. The concentration dependent effect of nitric oxide.
In addition to concentration, the availability of gaseous oxygen and reactive oxygen 
species is decisive for the cytotoxic effect of NO. A high concentration of oxygen 
results in formation of NO2 and NOOH-, which are highly reactive and cytotoxic, 
whereas a lower concentration is associated with formation of N2O3. The latter is 
admittedly a weak oxidant, but still results in cellular damage by binding to amines 
and thiol groups, especially in a hypoxic environment68.
1.3.4 In apoptosis
Apoptosis is thought to be mediated by two pathways. Extrinsically, when FAS 
death receptors are activated by extracellular signals, or an intrinsically, starting 
in the mitochondria. Both of these pathways are affected by NO69.
The effects of NO on apoptosis seem to be dependent not only on the target cell 
type, but also upon the cellular location of NO and its concentration. Apart from 
direct damage to DNA, NO also targets a number of proteins involved in apop-
tosis. The effects herein are both pro- and anti-apoptotic and include the proteins 
caspases, p53, B-cell lymphoma protein 2 (BCL-2), poly ADP-ribose polymerase 
(PARP), cytochrome C oxidase and FAS death receptors. Cytochrome C oxidase 
is the final step of the electron transport chain of the mitochondria. NO competes 
at high concentrations with oxygen for its binding site and blocks Cytochrome C 
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oxidase activity when bound, resulting in impaired cell respiration and subsequent 
apoptosis. Other possible mechanisms of mitochondria-associated apoptosis are 
NO-derived activation of mitochondrial permeability transition (MPT) and oxi-
dation of mitochondrial phospholipids, which leads to leakage of cytochrome C 
and activation of caspase cascades69. For PARP, an enzyme involved in both DNA 
repair and apoptosis, the picture is ambiguous, since NO, exerts both inhibition 
and activation depending on its concentration70. p53, “the gatekeeper protein”, that 
maintains genetic stability of the cell, and induces either cell arrest or apoptosis 
after DNA damage, is affected by nitrosative stress. In vitro, an accumulation of 
p53 has been observed in cells that were given NO-donors and in tumor cells that 
were transfected with NOS2. The complex role of p53 is enlightened by the fact 
that it by itself inhibits NOS271. In an in vivo study, where rats were given thyroid 
tumors that had been either variably transfected with NOS2, those tumors with 
NOS2, showed a higher degree of apoptosis compared to those without NOS trans-
fection. A high rate of apoptosis in combination with a low rate of transfected cells 
indicated that NO rather than the transfection itself was the cause of the apoptosis72.
The proliferative impact of NO also includes anti apoptotic effects. S-nitrosylation 
prolongs the half-life of Bcl-2, an anti-apoptotic enzyme. Binding of NO to sGC 
and the activation of cGMP results in a reduced influx of calcium, which in turn 
is associated with reduction in apoptotic signaling. Another possible mechanism 
is NO-induced inactivation of caspases mediated by S-nitrosation70.
1.3.5 In cancer
1.3.5.1 General aspects
There is multiple evidence that NO is involved in carcinogenesis73. By binding to 
metallo-complexes and sulfur residues in nucleic acids and proteins, NO causes 
DNA damage both directly from DNA strand breaks, and indirectly from inhibition 
and mutation of enzymes involved in DNA repair, such as PARP, and apoptosis, 
such as p53 and caspases73. 
The concentration of NO and the duration of biological exposure are critical factors 
when analyzing the effects of NO in toto. In general, long-lasting low concentration 
of NO promotes tumor growth and progression while in comparison a substantially 
high concentration of NO, has a cytotoxic and proapoptotic effect, inhibiting tumor 
growth74. A long-lasting, low concentration of NO has been observed to promote 
epithelial mesenchymal transition, angiogenesis, invasiveness and metastasis 
of tumors, thus influencing almost all aspects of tumor progression66. The NO 
 threshold for positive versus negative outcomes has not yet been identified, and 
indeed appears to differ depending on previous exposure. Acquired resistance to 
NO has been detected, and suggests that previous exposure to NO offers protec-
tion to a secondary higher dose exposure75.
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Figure 6. The dual role of nitric oxide in cancer. 
In the majority of published studies, an increased expression of NOS2 in primary 
tumor tissue is associated with a poorer prognosis. This association has been 
observed in bladder cancer, but also in other tumor types such as colorectal cancer, 
ventricular cancer43,76,77. In contrast, low expression of NOS2 was associated with 
progression and metastasis in pancreatic cancer studies done in mice78.
Tumor microenvironment is crucial to tumor growth, immune system evasion and 
progression. The interaction between tumor cells and surrounding cells such as 
fibroblasts, immunocytes and endothelial cells determines tumor evolution65. The 
presence of tumor-associated macrophages (TAM) has both positive and negative 
effects on overall tumor growth and outcome79. Depending on different environ-
ment stimuli, these cells appear polarized into two types; M1 macrophages that 
are cytotoxic and a major effector cell of the innate and specific immune response, 
and M2 macrophages that are wound healing and dampen immune response. M1 
macrophages are thought to be induced by bacterial and tumor antigens, IFNγ and 
TNFα, and are characterized by the expression of NOS2 and a high production of 
NO, whereas M2 macrophages are thought to be induced by parasites, IL-4 and 
IL-10. Interestingly, M2 macrophage activation is associated with a high expres-
sion of arginase, which (in theory) leads to a depletion of arginine in the cell and 
surrounding tissue and results in a reduced production of NO. It has thus been 
suggested that M2-macrophages contribute to a microenvironment that promotes 
tumor growth and immune evasion by an indirect lowering of NO, while M1 
macrophages do the opposite60. The M1/M2 ratio seems to be important and may 
indicate a role for NO in tumor evolution generally. In colon cancer, tumors with 
a high number of macrophages expressing NOS2, were associated with better 
outcomes80.
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1.3.5.2 NO in bladder cancer
Evidence to support NOs importance in bladder cancer pathophysiology and treat-
ment is scarce. Several studies, in vitro and in vivo, however, indicate that NO 
might have a role to play in the development of bladder cancer. 
NOS expression and NO formation in bladder cancer: Bladder tumor cells are 
able to express NOS2 and form NO under certain circumstances. In the 1990’s 
Konur et al showed that in vitro co-stimulation of bladder tumor cells with macro-
phages resulted in NO formation81. There are conflicting results whether NOS2 is 
normally present in unstimulated urothelium or not. In some bladder tumor tissue 
however, NOS2 is expressed at an increased rate, a fact that has been shown in 
several studies82,83. NOS2 is expressed in tumor cells and also by cells like macro-
phages in the surrounding stroma39. Increased amounts of NO in the bladder have 
been recorded among patients diagnosed with bladder cancer84, particularly those 
with CIS and the formation of NO may thus be dependent on the type of tumor85. 
In summary, studies show that in some cases urothelial cancers express NOS2, a 
finding that was occasionally also associated with an increased concentration of 
NO in the bladder mucosa or urine of these patients.
Negative and positive effects: Like in other tumors, NO seems to have both 
negative and positive effects in bladder-cancer. Tumor cells are probably more 
sensitive to NO than normal urothelial cells. Normal urothelium cells were not 
affected when NO was given in vitro, however NO was cytotoxic to bladder  cancer 
cells in a reaction that was reversible with NO-inhibitors86. In in vitro studies, 
Wang et al showed that the addition of NO was associated with a proliferation of 
lymphokine-activated killer-cells (LAK) involved in tumor eradication87 and Tan 
et al found that bladder cancer cells that produced NO after NOS2 gene transfer, 
also increased apoptosis and expression of factor p5388. 
NO-induced apoptosis, however, is of questionable importance in bladder cancer 
cases. The presence of arginase in the bladder mucosa of bladder cancer patients 
may indicate that the tumor cells are adapting to increased amounts of NO63. There 
is also evidence that NO is beneficial to the tumor. NOS3 and NOS2 have been 
associated with an increased angiogenesis in bladder cancer89 and tumor expression 
of NOS2 among bladder cancer patients, was associated with a poorer prognosis90. 
In NMIBC patients, the presence of NOS2 in the tumor, has been associated with 
a higher recurrence rate43,91. In murine studies, expression of NOS2 in the tumor 
was associated with an increased metastasis risk, whereas mice that were given 
the NOS2-inhibitor L-NAME, had a decreased risk of metastasis90,92.
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1.3.5.3 BCG and NO in bladder cancer
Earlier studies in our group have shown increased levels of NO in the urinary 
bladder of BCG-treated patients and expression of NOS2 in the bladder mucosa 
of BCG-treated bladder cancer patients93. NO-concentration increased with an 
increased number of instillations, and NO levels stayed at increased levels for 
months after treatment completion94. 
Macrophages and bladder mucosal urothelial cells in vivo form NO with BCG 
stimulation95. The exact role of NO in the BCG-reaction is unclear, but further studies 
suggest that NO may be a critical factor in the BCG-mediated anti-tumor effect. 
NO mediates macrophage cytotoxicity in an arginine-dependent reaction49. A 
 number of factors have been identified, in vivo and in vitro that trigger macro-
phages to form NO. These factors are both endogenous soluble proteins, such 
as the cytokines IFNγ and TNFα, and exogenous, invasive pathogens such as 
Mycobacterium bovis and E. coli. The cytokines IFNγ and TNFα are also involved 
in macrophage cytotoxicity. Cell to cell-contact is also critical for the cytotoxic 
effect of macrophages. Tumor type is another important factor.
The results of in vitro studies of the direct cytotoxic effect of BCG and NO on 
bladder tumor-cells have been contradictory. In vitro studies show that, T24 and 
MBT2 bladder tumor-cells express NOS2 and NO upon BCG stimulation, without 
adjuvant stimuli, and that this results in cell death. Further more, the formation of 
NO was reversible with NOS-inhibitors96. In direct contrast to these results, other 
research groups showed that macrophages and lymphocytes are necessary for 
BCG-induced NO-formation and cytotoxicity97,98. These latter studies are supported 
by the well-established assumption that an intact immune system is a prerequisite 
for the anti-tumoral activity of BCG20. Viability of BCG is also crucial21 as high 
NO concentrations are toxic to BCG mycobacteria, a fact that may have clinical 
significance. In an in vitro study of BCG-stimulated macrophages, addition of 
NOS2-inhibitors promoted survival of intracellular BCG along with increased 
macrophage-derived cytotoxicity98. 
Over all, there is uncertainty on the role of NO in the anti-tumor effect of BCG. 
Whether NO acts as a substantial tumor-inhibitor in BCG-treatment, or if it is just 
a marker for BCG-related immunological activity, is yet to be clarified.
1.3.6 Influence of NOS polymorphisms
Polymorphism in biology is the presence of different variants or morphs, in a par-
ticular population of a single species. In medicine, polymorphism is used almost 
invariably for genes. Genetic polymorphism was defined in 1971 by Cavalli-Sforza 
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and Bodmer as “…the occurrence in the same population of two or more alleles at 
one locus, each with appreciable frequency, where the minimum frequency is typi-
cally taken as 1%”99. The most common existing variant of a gene in a population 
is named the wild type allele, while the others are called rare or variant alleles. 
The distribution of genes varies in different populations, and therefore the wild-
type allele is population specific. Polymorphic studies of one group, may not be 
 generalizable to other populations - a genotype that is beneficial in one environment 
for one disease burden, is not in another milieu, where group health faces another 
panorama of threats. Polymorphisms are present in every gene of an individual, 
and may be associated with vulnerability to infectious diseases and cancer100. 
The first evidence of the importance of genetic polymorphisms in disease develop-
ment was reported in the 1960’s. A number of gene variants of erythrocytes were 
linked to susceptibility to malaria and explained the occurrence in certain areas 
and populations, of diseases such as sickle-cell anemia and thalassemia101. Another 
field of interest was cancer, and early works in the 1980, included studies on HLA 
polymorphism and leukemia, and CYP polymorphism and lung cancer102. 
There are only a few familial cancers that are caused by a single known mutation 
in a tumor suppressor gene. Most hereditary factors however are due to lower risk 
genetic polymorphisms, that affect the susceptibility for developing a cancer103. 
These genes might influence specific proteins such as enzymes involved in cell 
cycle control, DNA repair mechanisms and the metabolism of toxic substances 
that are in turn affected in cancer.
Heritable factors have been estimated to cause 1/3 of all bladder cancer cases6, how-
ever, familial cases are scarce and only a few syndromes, such as Lynch  syndrome, 
have been identified. Therefore, lower risk genes and their polymorphism may 
play a greater role than previously thought. There has been a particular interest 
in the interplay between environmental exposure and certain polymorphisms of 
enzymes involved in bladder carcinogen metabolism. Exposure of carcinogens 
such as aromatic amines have been linked to certain morphs of GSMT1 and UDP 
glucoronosyltransferase 1a gene (UGT1a)8. How these polymorphisms are linked 
to bladder tumor carcinogenesis is still poorly understood, although several genes 
involved in DNA repair and metabolism, have also been associated with p53 
 mutations5. Various morphs of genes that code for inflammatory mediators other 
than NO, have been associated with an increased risk of bladder cancer. Among 
them are genes coding for IL4 and IL6, the latter also associated with outcome 
after BCG treatment104,105. The results, however, are inconsistent and vary according 
to ethnic origin and carcinogenic exposure. Although there are many candidates, 
so far no gene polymorphisms are used as a predictive tool in BCG treatment of 
bladder cancer.
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For NOS genes, there are a number of polymorphisms of carcinogenic importance 
that influence tumor progression and disease specific mortality. 
Polymorphisms in the promoter region of NOS have been associated with greater 
risk and poorer prognosis in ventricular and lung cancer106,107. Intragenic single 
nucleotide polymorphisms (SNP) in the NOS gene are also of interest. While 
rs1799983 (Glu298Asp), an intragenic NOS3 gene SNP, has been associated with 
increased risk of ovarial cancer108, rs2297518(Ser608Leu), an intragenic NOS2 
SNP, has been associated with gastric cancer109. 
For bladder cancer, there are still only a few NOS gene polymorphisms associ-
ated with carcinogenesis and survival. In our group we have previously studied 
a  number of genes. Variants of a microsatellite (CCTTT)n repeat polymorphism 
in the promoter region of the NOS2 gene were associated with an increased 
 expression of NOS2110,111. People with these variants also had a lower incidence of 
bladder cancer. In bladder cancer patients however, the same variants were associ-
ated with an impaired prognosis and a reduced cancer specific survival112. For the 
NOS2 intragenic polymorphism rs2297518(Ser608Leu) there was a variant that 
was associated with an increased incidence of bladder cancer but a reduced risk 
of progression113. For the NOS3 promoter polymorphism rs2070744(-786T>C) 
there were variants associated with an increased risk for bladder cancer and for the 
NOS3 intragenic polymorphism rs1799983 (Glu298Asp) genotype was associated 
with grade114. Exactly how these polymorphisms of NOS2 and NOS3 influence 
the expression of NOS2 and NOS3, and the formation of NO, and other pathways 
of influence on bladder cancer, remain unknown.
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2 AIMS OF THE STUDY
1. To analyze whether TUR-BT with adjuvant intravesical BCG is superior to 
TUR-BT alone in patients with high-risk NMIBC.
2. To analyze whether nitric oxide synthase-polymorphisms, the NOS2-promoter 
microsatellite(CCTTT)n, and the NOS3 promoter polymorphism rs2070744 
(-786T>C) and the NOS3 intragenic polymorphism rs1799983 (Glu298Asp), 
are possible markers of outcome after BCG-treatment for NMIBC.
3. To investigate the role of macrophage secreted factors (MSF) from BCG-
stimulated macrophages on bladder cancer cells.
4. To analyze the influence of macrophage secreted factors on NO-production 
and cell death in bladder cancer cells.
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3 MATERIALS AND METHODS
3.1 Study populations and clinical assessment (Paper I–III)
In Paper I, the study population consisted of 29 NMIBC patients planned for BCG 
treatment. In all patients, the risk of recurrence or progression was assessed as 
intermediate to high.
In Papers II and III the study populations consisted of a well-defined cohort of patients 
diagnosed with bladder cancer. Over a period of 2 years, from 1st of January 1995 to 
31st of December 1996, all patients newly diagnosed with urothelial carcinoma (UC) 
in the Stockholm County were asked to participate in a prospective cohort study. 
In total 538 patients, 76% (538/705) of all patients in the county during that period 
agreed to participate. The entire cohort was described in a 5-year clinical follow-
up in 200311 and in an additional article in 2010115. Parameters registered initially 
were; date of diagnosis, sex, age, stage, grade, tumor size, tumor multifocality, pres-
ence of concomitant CIS, and presence of detrusor muscle in the resected material. 
The same pathologist reviewed all histopathological assessments and the standard 
pathological report included data on stage, grade, presence of  concomitant CIS, 
and detrusor muscle in the specimen. Histopathological classification followed the 
tumor, node, and metastasis (TNM) classification from 1978116. For tumor grading, 
the WHO 1999 malignancy grading system was applied117. High-risk NMIBC was 
defined as all non-muscle-invasive T1 and all G3 tumors, e.g., T1G1–G3, TaG3, 
and primary and secondary CIS, according to EAU standards118 and previous results 
from our group11.
Patient records of all the original participants of Paper II and III were scrutinized 
in 2011. At that time, all surviving patients had been routinely followed up over 
a 15-year period. The other patients had died from either urothelial carcinoma or 
from other disease, as reported in the Swedish Cause of death Register. Follow-up 
time was defined as the time elapsed from date of diagnosis to death or last clinical 
evaluation. A number of parameters were collected from patient files in the follow-
ups after 5 and 15 years. For our studies, we considered the following being most 
relevant; number and date of recurrence, and date of progression to muscle-invasive 
tumor, development of lymph-node and distant metastasis, type of therapy, and 
date and cause of death. For the polymorphism study, data on NOS2 and NOS3 
genotype were also registered. Recurrence was defined as diagnosis of any new 
tumor in the bladder after the initial staging and grading by TUR-BT. Progression 
was defined as growth of the initial tumor into the muscular layer of the bladder or 
beyond, appearance of local and distant metastasis or death from bladder cancer. 
Cancer specific mortality was defined as death from bladder cancer as reported in 
the Swedish cause of death register. In the cases where progression had not been 
reported before Cancer specific mortality, patient files were checked for other 
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 possible causes of death. In cases where cause of death was registered as bladder 
cancer without any previous progression, date of progression was considered as 
the same as date of death. All patients included in the 5-year clinical follow-up 
were also included in the 15-year follow up. 
In Paper III, all 140 patients with high-risk NMIBC from this patient material were 
included. Of the 140 patients, 1 was excluded due to inconsistent data, 82 were 
treated with BCG and 57 were not. We genotyped 88 of these 140 patients using 
venous blood samples. Of these 88 patients 51 had received BCG-treatment and 
37 had not. These patients were included in the in Paper II. 
The polymorphisms investigated in Paper II; the NOS2 promoter  microsatellite 
(CCTTT)n polymorphism, the NOS3 promoter polymorphism rs2070744 
(-786T>C), and the NOS3 polymorphism rs1799983 (Glu298Asp), were chosen for 
the following reasons; all 3 had previously been associated with an altered produc-
tion of NO and expression of NOS2 and NOS3 respectively110,119,120 and all 3 had 
also been associated with the development and progression of bladder cancer112,114.
Informed written consent was obtained from all participants across all three  studies. 
The studies were approved by the regional Ethical Committee.
3.2 Tissue collection (Paper II)
Tumor tissue from all of the 538 participants of the study was collected during the 
initial TUR-BT in 1995 and 1996. Venous blood (normal tissue) from 359 of these 
participants was collected at a later time point and genotyped for the NOS2 (CCTTT)
n promoter microsatellite polymorphism, the NOS3 promoter polymorphism 
rs2070744(-786T4C), and the NOS3 exon 7 polymorphism rs1799983(Glu298Asp). 
88/359 of the participants of whom normal tissue was collected were included in 
the present study. These 88 participants were all patients with high-risk NMIBC.
3.3 Cell culture AND treatments (Paper I)
Cell cultures of human bladder cancer cells (MBT2, T24 and J82) were maintained 
in RPMI supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine 
(Invitrogen). In cell cultures of the monocyte/macrophage Raw 264.7, RPMI was 
replaced by Dulbeccos modified Eagle’s medium (DMEM) and in addition to 
FBS and L-glutamine supplemented with 100 nM β-mercaptoethanol and 50 μg/l 
of Pyruvate (Invitrogen). Cells were kept in cultures in a humidified incubator at 
37 °C, 5% CO2, and plated the day before treatments.
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3.3.1 Treatments
BCG (Medac) was reconstituted in FBS or DMEM, depending on cell type, and 
administered to tissue culture at a final concentration of either 0,5×106 or 5×106 
CFU/ml. Lipopolysaccharides from E-coli (LPS, Sigma Aldrich) and IFNγ (Sigma 
Aldrich) were added to the cell cultures as indicated, in order to provoke NOS 
expression. For experiments where MBT2 cells were treated with supernatant 
from RAW 264.7 macrophages, macrophages were treated one day before MBT2 
cells. On the next day 40 % of the growth medium was replaced with centrifuged 
media from untreated and BCG-treated macrophages. NG-Nitro-L-arginine-methyl 
ester (L-NAME, Enzo Life Sciences), was used for inhibition of the enzymatic 
formation of NO.
For the in vivo detection of NO in NMIBC patients, the induction course comprised 
6 once weekly intravesical instillations of BCG (BCG-Medac, 2×108-3×108 colony 
forming units dissolved in 50 ml of saline solution). NO-values in patients were 
recorded, and patients with acute or chronic urinary tract infection UTI), detected 
with urine test sticks (Multistix®5) and confirmed with urine culture, were excluded 
from the study, as were patients with less than four registered NO-values. At the 
end 24/29 patients were included in the study results.
3.3.2 RNA extraction and cDNA synthesis
RNA isolation from cell lines was performed by using TRIzol-chloroform  extraction. 
In order to lyse the cells and separate the RNA from other cellular components, 
attached cells were lysed in TRIzol (1 ml) and chlorophorm (200 μl), shaken and 
incubated for 3 minutes, and centrifugated (12000×g) for 15 minutes. The aqueous 
phase containing RNA, now separated from lipids and proteins, was then transferred 
to a new tube and mixed with isopropranol, incubated and centrifugated for 10 
minutes, and the supernatant was removed. The remaining RNA pellet was then 
washed in 75 % ethanol, air dried, dissolved in DEPC water and stored at -70 °C. 
RNA integrity was confirmed by using a Bioanalyzer (Agilent Technologies). For 
real-time PCR, 2 μg RNA was converted to cDNA by using the High Capacity 
cDNA reverse transcription kit (Applied Biosystems).
3.3.3 Real-time PCR
NOS2 mRNA along with the expression of 95 other genes (including expression 
of 8 reference genes) was measured by using a TaqMan® Array Mouse Immune 
Panel. Each array card contained four ports and was loaded with one untreated 
control sample and three treated samples. Real-time PCR was performed in an 
Applied Biosystems 7900HT system using default settings (Applied Biosystems). 
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Expression curves were manually re-analyzed and checked. Change in target-gene 
expression in relative to untreated control was calculated from the comparative 
Ct method using 2-ΔΔCT. Reference genes were used to quantify the target genes.
3.3.4 Immunoblot analysis
Protein expressed within the cultured cells, was extracted and separated from other 
cellular content, by lysing the cells in EBC lysis buffer (Tris, NaCl 120 mM, 0.5 % 
NP40, NF 100 nM, Sodium Orthovandate 0.2 mM, PMSF 10 μg/ml, Apoprotinin 
10 μg/ml, b-glycerophosphat 50 μg/ml)(Sigma Aldrich), and then centrifuged at 
14000 rpm for 20 minutes at +4 °C. Bradford protein assay (Bio-Rad laboratories) 
was used to determine the protein content of the supernatant fluid. Electrophoresis, 
using a 4-8% SDS Pierce ProteinGel (Thermo Scientific) was used to separate the 
investigated proteins; NOS2, β-actin and PARP, from other proteins. The  proteins 
were then transferred onto PVDF membranes using wet blot or an iBLOT, and then 
blocked with 0,5% BSA for one hour. Application of antibodies was performed in 
2 steps, firstly with either a NOS2 antibody (BD-Biosciences), a β-actin antibody 
(Sigma Aldrich) or a PARP antibody (Cell Signaling) over night and then consecu-
tively with HRP-conjugated secondary antibody. These secondary antibodies and 
a chemiluminescent substrate (Thermo Fisher Scientific) were used to detect the 
final protein signals on autoradiographs (Kodak X-O mat 2000 processor). Mouse 
macrophages and urothelial cancer cells stimulated with LPS and interferon-γ 
were used as positive controls for NO and NOS2 detection. All reagents were 
used according to the manufacturer’s instructions.
3.3.5 Growth Experiments
The presence and absence of viable BCG and bacterial contamination in growth 
experiments with macrophages (RAW) and bladder cancer cells (MBT2) were 
determined in the media from untreated and BCG-treated cell cultures. After cen-
trifugation (14,000 rpm, 5 min) of the media, a fraction of the pellet or supernatant 
was plated on agar plates, dried, and then incubated at 37 °C in humidified plastic 
bags. Bacterial growth was checked weekly for eight weeks. The input fraction of 
BCG was used as a positive control and untreated supernatants and sterile filtered 
supernatants were used as negative controls.
3.3.6 Cell Cycle Analysis
The DNA-content of every cell, as proportional to the phase in the cell cycle, was 
determined with flow cytometry (FACS) after staining DNA with propidium iodide 
using the CycleTest Plus DNA reagent kit (BD-bioscenses).
In all experiments, kits were used according to the manufacturer’s instructions.
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3.4 NO determination (Paper I)
3.4.1 In cell lines
Sealed tissue culture flasks were incubated at 37 °C for 4 hours, 25 ml of air was 
aspirated from the headspace of each culture flask using a syringe and infused into 
a chemiluminiscense NO analyzer (CLD 700, Eco Physics, Durmen, Switzerland) 
to measure peak levels of NO. 
3.4.2 In the human bladder
Intramucosal NO concentration was measured using a previously described and 
validated method121. First a silicon catheter was introduced into the bladder. The 
catheter balloon was filled with 25 ml of room air via sterile syringe. After 5  minutes 
the air was re-aspirated into the same syringe and subsequently infused into a chemi-
luminiscense NO analyzer (CLD 700, Eco Physics, Durmen, Switzerland), where 
peak levels of NO were determined. Air from the examination room was collected 
concurrently with the procedure and analyzed for NO content. This background 
NO level was then subtracted from patient NO levels. The lower detection limit 
was 1 part per billion (ppb). Calibration of the analyzer was performed regularly 
using an electromagnetic controller with known concentrations of NO in N2.
3.5 Genotyping methods (Paper II)
3.5.1 Fragment analysis
The NOS2 (CCTTT)n microsatellite promoter polymorphism was analyzed by DNA 
fragment analysis with a ABI Prism 3730® Genetic Analyzer (AppliedBiosystems). 
PCR primers, used for the amplification of analyzed gene sequence, were designed 
with Primer3 software and the forward primer was labelled with 6FAMTM. PCR 
was performed using 13 μl reactions containing PCR buffer, MgCl2, dNTP, 
AmpliTaqGold DNA-polymerase (AppliedBiosystems) and primer according to 
the manufacturer’s instructions. After 45 cycles of amplification, 1 μl of the PCR 
product was mixed with HiDi-formamide (AppliedBiosystems) and GeneScan-500 
Liz Size Standard (AppliedBiosystems), heated for 3 min at 95 °C and cooled on 
ice. The sample was analyzed for DNA fragments using a ABI Prism 3730® Genetic 
Analyzer and data was analyzed with a ABI GeneMapper-v.4.0.
3.5.2 Allelic discrimination
The NOS3 polymorphisms rs2070744(-786T4C) and rs1799983(Glu298Asp) were 
analyzed by allelic discrimination on an ABI Prism® 7900HT sequence detection 
system (AppliedBiosystems). TaqMan primers and probes were purchased from 
AppliedBiosystems. PCR was performed using 5 μl with 10 ng DNA as a template. 
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The genotyping of amplified PCR products was scored by differences in VIC and 
FAM fluorescent levels in plate red operation on ABI Prism® 7900HT sequence 
detection system (AppliedBiosystems) using SDS-2.2.1. software. 
3.5.3 DNA sequencing
To verify authenticity of amplified sequences, 10% of the bladder cancer patients and 
population controls, were randomly chosen for DNA sequencing. ExoSAP-IT (GE 
Healthcare)treated PCR products together with a sequencing primer were added to 
sequencing reactions, performed with a BigDye® Terminator Cycle sequencing kit 
(AppliedBiosystems). After treatment with BigDye® Xterminator, reaction  products 
were loaded onto an ABI prism 3720 Genetic analyzer (AppliedBiosystems). 
Analysis of the data was done by using Sequencing Analysis 5.2 software 
(AppliedBiosystems) and 4 peaks (http://mekentosj.com/programs).
3.6 Study design (Paper II)
In Paper II, patients that were homozygous for a long set of repeats, (≥13) of 
the NOS2(CCTTT)n microsatellite, were compared with patients who were not 
homozygous for a long set of repeats. For the NOS3 polymorphisms, due to the 
low frequencies of patients homozygous for the minor alleles (C in rs2070744, and 
T in rs1799983), these were grouped together with patients heterozygous for the 
2 alleles (CT in rs2070744 and GT in s1799983) and compared with the patients 
who were homozygous for the most common allele (TT in rs207074 and GG in 
rs207074). When performing the genotyping the researcher had no knowledge of 
treatment modality.
3.7 Statistical analysis (Paper I, II and III)
Paper I: All assays were done with a minimum of 2 independent experiments. The 
results were expressed as the mean±S.E.M. Differences between the groups were 
analyzed by ANOVA with the least significant difference as post hoc. The associa-
tion between intravesical NO concentration and the number of BCG instillations 
was also analyzed with 1-way Anova trend analysis and polynomial regression. 
For statistical calculations SPSS statistics, version 20, was used.
Paper II: Patients with certain genotypes who received BCG were compared 
with patients who did not, in terms of recurrence, progression and CSM. Among 
patients who received BCG, patients with one particular genotype were compared 
with patients with other genotypes in terms of recurrence, progression and CSM. 
Univariable analysis of each of these terms was done for Kaplan- Meier survival 
estimates and curves using the Mantel-Cox log-rank test. Multivariable Cox pro-
portional regression with stepwise selection was used to calculate hazard ratios 
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(HR), and to verify the prognostic significance of clinicopathological factors of 
significance (age, sex, stage and grade). Associations between the polymorphisms 
were calculated with linkage disequilibrium and Pearson’s coefficient of correla-
tion. HRs are shown with a 2-sided 95% confidence interval (CI). For statistical 
calculations SPSS statistics, version 21.0, was used.
Paper III: Patients who received BCG were compared with patients who did 
not, in terms of recurrence, progression, and CSM. Univariable analysis of each 
of these terms was done for Kaplan-Meier survival estimates and curves using 
the Mantel-Cox log-rank test. Multivariable Cox proportional regression with 
stepwise selection was used to calculate hazard ratios (HR), and to verify the 
prognostic significance of clinicopathological factors of significance (age, sex, 
stage, grade, tumor size, multiple tumors, and concomitant CIS). In many studies, 
CIS is considered a separate entity. Separate analysis with and without CIS and 
concomitant CIS were, therefore, carried out in Paper III. HRs are shown with a 
2-sided 95% confidence interval (CI). For statistical calculations SPSS statistics, 
version 21.0, was used.
In all of the 3 papers, p<0.05 was considered statistically significant.
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4 RESULTS
4.1 Paper I 
Our earlier observation, that NO is formed in the bladder of bladder cancer patients 
during BCG treatment, was confirmed in a larger cohort in vivo93. In the present study 
we discovered that the concentration of NO increases with an increasing number of 
instillations (p=0.001), but with a substantial inter-individual variation (See Fig. 7).
Figure 7. Intra-bladder nitric oxide concentrations after BCG-instillation displayed as 
a boxplot. The boxes represent IQR for each instillation, the band in each box the median 
value, whereas the whiskers are set at the highest and lowest (outliers excluded) values 
respectively. BCG Bacillus Calmette-Guérin IQR inter quartile range.
In vitro we discovered BCG to be cytotoxic to both murine bladder tumor cells 
(MBT2) and macrophages (RAW264.7). Cytotoxicity was dependent on macro-
phages. BCG induced apoptosis in MBT2 and RAW264.7 cells in a concentration 
and time dependent manner. This reaction was independent of NO and not affected 
by the addition of NOS inhibitors.
When RAW macrophages were stimulated with BCG, we also detected NO in a 
dose dependent release that corresponded to an increase in intracellular NOS2 
mRNA and NOS2 protein expression. In contrast to RAW macrophages, stimula-
tion of MBT2-cells with BCG did not result in detection of NO nor an increase in 
intracellular NOS2 mRNA or NOS2 protein expression in MBT2 cells (See Fig. 8)
When stimulated with BCG, RAW macrophages excreted a number of soluble factors. 
When the supernatant from these BCG-treated macrophages was added to the tissue 
culture media, a slight increase of NOS2 mRNA and NOS2 protein expression and 
NO formation was detected in the MBT2 cell culture (See Fig. 9)
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Figure 8. Nitric oxide formation (A) and NOS2 expression (B(mRNA) and C and 
D(protein)) in MBT2 cells and RAW264.7 according to treatment (No NCG, 0.5×106 
or 5×106 BCG for 24 h). BCG Bacillus Calmette-Guérin.
Figure 9. Nitric oxide formation (A) and NOS2 expression (B(rtPCR) and C(western blot)) 
in MBT2 cells after adding supernatant from BCG treated macrophages (RAW264.7) to 
the  culture medium. MBT2 cells were treated with supernatants from untreated RAW264.7 
cells or cells treated with 0.5×106 or 5×106 BCG and/or L-NAME (100μl). BCG Bacillus 
Calmette-Guérin.
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PARP cleavage, an indicator of apoptosis, was seen only in MBT2 cells treated 
with supernatant from BCG-stimulated macrophages. When L-NAME, a NOS2 
inhibitor, was added to the macrophage culture media before BCG-treatment, 
apoptosis was not affected. (See Fig. 10)
Addition of supernatant from the non-BCG treated macrophage culture resulted 
in cell death among MBT-2 cells. The magnitude of cell death in the MBT2 cell 
culture increased, when BCG was administered to the macrophages. (See Fig. 10)
Figure 10. Cell cycle profiles after BCG-treatment. Propidium iodide stained MBT2 cells 
visualized by FACS analyses. (A) Cell cycle distribution among MBT2 cells according to 
treatment (no BCG, BCG, supernatant from untreated or supernatant from BCG-treated 
RAW 264.7 macrophages) (B) Cell death among MBT2 cells measured as the debris 
fraction in sub G1 and visualized as fold increase of fraction of cells in sub G1, according 
to treatment (as in (A)). BCG Bacillus Calmette-Guérin.
In an assay (TaqMan® Array Mouse Immune Panel) where expression of 95 inflam-
matory genes was measured in BCG-treated cells against an untreated control, 
BCG-treated macrophages had an increased expression of NOS2 and 26 additional 
genes. When tested in MBT2 cells immediately after BCG-treatment, only 3 of 
these additional genes (NOS2 not among them) showed increased expression.
4.2 Paper II
In this study we investigated the influence of previously identified NOS poly-
morphisms on stage progression and cancer specific survival after BCG treatment 
in patients with high risk NMIBC.
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We investigated one NOS2 polymorphism and two NOS3 polymorphisms, of 
which all three influenced Cancer specific mortality (CSM) after BCG treatment, 
while the latter two also influenced outcome in terms of progression. 
For the NOS2 (CCTTT)n microsatellite promoter (-2,6kb) polymorphism, geno-
typing was successful in all patients, of whom 51 had received BCG. BCG impact 
on CSM was associated with a short set of repeats (L<13). The risk of CSM in 
this group of patients (n=43) was significantly reduced for those who had received 
BCG compared to those who had not (HR: 0.12; CI: 0.02-0.98 p=0.048). Among 
patients with a long set of repeats (n=45) there was no statistically significant 
difference in CSM between those who had been treated with BCG and those who 
had not. (See Fig. 11)
Figure 11. CSS and progression according to treatment (BCG or not) among patients with 
different variants of NOS2 (CCTTT)n microsatellite promoter polymorphism (L-carrier 
or Non L-carrier). BCG Bacillus Calmette Guérin  CSS Cancer Specific Survival.
For the NOS3 promoter -786T<C (rs2070744) polymorphism, genotyping was suc-
cessful in 87/88 patients, of whom 50 had received BCG. For this  polymorphism, 
those with the TT genotype displayed reduced risk for CSM and disease progression 
after BCG, whilst patients with the CT/CC genotype did not benefit from BCG 
treatment in this regard. For the TT genotype, none of the patients who received 
BCG (n=21) experienced CSM compared to 7 out of 18 patients with who did 
not receive BCG. Also regarding progression, patients with the TT genotype 
had a reduced risk of progression after BCG-treatment (HR; 0.05; CI:0.01-0.42 
p=0,005). (See Fig. 12)
CSS Progression
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Figure 12. CSS and progression according to treatment (BCG or not) among patients 
with different variants of NOS3 promoter -786>C polymorphism (TT or CT+CC). 
BCG Bacillus Calmette Guérin  CSS Cancer Specific Survival.
For the NOS3 exon Glu298Asp (rs1799983) polymorphism, genotyping was 
 successful in 64/88 patients, of whom 34 had received BCG. For this polymorphism, 
reduced risk for CSM and disease progression after BCG treatment were associ-
ated with the GG genotype, whereas patients with the GT/TT genotype did not 
benefit from BCG treatment in this regard. For the GG genotype, BCG treatment 
was associated with a reduced risk of CSM (HR: 0.16; CI: 0.03-0.84 p=0.030). 
Also regarding progression, patients with the GG genotype had a reduced risk of 
progression after BCG-treatment (HR; 0.10; CI:0.02-0.46 p=0,003). (See Fig. 13)
Figure 13. CSS and progression according to treatment (BCG or not) among patients 
with different variants of the NOS3 exon Glu298As polymorphism (GG or GT+TT).
BCG Bacillus Calmette Guérin  CSS Cancer Specific Survival
CSS Progression
CSS Progression
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When the effects of these polymorphisms were combined in all patients who received 
BCG-treatment (n=51), patients with one or more of either NOS2 (CCTTT)non-L-
carrier (homozygous), NOS3-rs2070744 TT or NOS3-rs1799983 GG genotypes, 
had a significantly better cancer specific survival (HR: 0.20; CI: 0.05-0.85 p=0.029) 
after BCG-treatment compared to those patients (n=15) who did not have any of 
these genotypes. In conclusion, those patients who had genotypes associated with 
basal levels of NO had benefit from BCG treatment as opposed to those who had 
genotypes that either increased or decreased the basal levels of NO (See figure 14).
CSS
Figure 14. CSS according to genotype (one or more of either NOS2 (CCTTT)non-L-carrier 
(homozygous), NOS3-rs2070744 TT or NOS3-rs1799983 GG genotypes, or not) among 
patients who received BCG treatment for bladder cancer. BCG Bacillus Calmette Guérin  
CSS Cancer Specific Survival.
4.3 Paper III
In this study we investigated the long-term effect of BCG treatment on recurrence, 
progression and cancer specific mortality.
139 patients with high risk NMIBC were identified and included. The majority of 
these patients, were high grade, size > 3 cm and staged as T1. BCG treated patients 
were younger (68.5 yrs. vs. 72 yrs.), of lower stage than T1 (68% vs. 93%), had 
more primary CIS (13% vs. 0%) and concomitant CIS (34% vs. 5%), and more 
G3 tumors (71% vs. 46%) than non-BCG treated patients. Detrusor muscle was 
obtained in as much as 83 % of the patients with T1 tumors, and similar in BCG 
treated and non-BCG treated patients (86 % vs 83 %). 
Within 15 years of clinical follow up, 50 (36%) patients experienced stage progres-
sion and 38 (27%) patients had died of urothelial carcinoma. The majority of these 
patients progressed and died within 5 years from diagnosis. Over all, most of the 
events, occurred within 10 years of follow up after diagnosis. (Patients who died 
from urothelial cancer were older at first diagnosis and at progression) (See Table 1).
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Table 1. Clinical outcome n (%). BCG Bacillus Calmette-Guérin, T2NM stage 2–4, 
lymph-node metastasis or distant mestastasis or CSM, CSM Cancer-specific 
Mortality
Alternative intravesical treatment was seldomly given and immediate cystectomy 
was performed in only 3 cases. When progression was diagnosed, cystectomy was 
the treatment of choice and performed in 25 patients. This treatment modality was 
more common in non-BCG treated patients as compared to BCG treated patients 
while the others were not. 
Patients that received BCG-treatment had lower rates of recurrence than the group 
that did not receive BCG (hazard ratio (HR): 0.40 p<0.0001). Also after exclusion 
of patients with primary CIS tumors (n=11) there was a statistically significant 
difference between the 2 groups (HR: 0.40 p<0.0001) (See figure 15).
For progression, the results showed a statistically significant difference between the 
BCG treated and the non-BCG treated group, both before (HR 0.52 p=0.038) and 
after exclusion of patients with primary and concomitant CIS (HR 0.41 p=0.018). 
However, after exclusion of primary CIS-patients, statistical significance fell below 
p<0.05 after adjustments for age and stage (HR 0.58 p:0=075) (See figure 16)
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Figure 15. Recurrence-free survival according to treatment (BCG or not).  
BCG Bacillus Calmette-Guerin.
Figure 16. Progression-free survival according to treatment (BCG or not).  
BCG Bacillus Calmette-Guerin.
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Death from urothelial carcinoma occurred at a lower rate in the BCG treated group 
as compared to the non-BCG treated group (20% vs 39%, HR 0.40 p=0.006 (see 
Table III)). However, after adjustments for age, stage, tumor size and number of 
tumors, no statistically significant difference could be measured (See figure 17).
Figure 17. CSM-free survival according to treatment (BCG or not).  
CSM Cancer Specific Mortality  BCG Bacillus Calmette-Guerin.
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5 DISCUSSION
The exact mechanism of action of BCG on bladder cancer is still in question. We 
need to understand how to identify non-responders, how to optimize treatments 
and decrease side effects, and ultimately which patients are most suitable for treat-
ment and will have the most favourable results. 
This thesis, examines the long-term effects and efficacy of BCG in bladder  cancer, 
and in line with previous research in our group, investigates possible roles of 
nitric oxide in the BCG reaction. The aim was to deepen the understanding of the 
BCG-reaction, and ultimately to identify a predictive marker for BCG-treatment of 
bladder cancer. We investigated the long-term efficacy of BCG at reducing recur-
rence, progression and cancer specific mortality (CSM); and more specifically if 
NO played a part in these processes.
5.1 Efficacy of BCG
BCG was introduced by Morales et al in 1976 as a treatment against superficial, 
recurrent and residual bladder tumors. In this first study when BCG was given in 
6 weekly instillations per urethram, only 1/9 patients experienced recurrent disease 
within the short follow-up (5 to 12 months). This study identified some of the by 
now well-known side effects of the treatment; dysuria, fever and malaise22. Morales 
observations on BCG regarding recurrence, were confirmed in several randomized 
trials and in 1990 BCG was approved by the Federal Drug Administration (FDA) 
for treatment of NMIBC. A large number of randomized studies, the majority 
of them comparing BCG with other intravesical treatments, e.g. mitomycin, 
interferon-α and epirubicin, showed that BCG reduces the number of recurrences 
after TUR-BT122. In order to improve the efficacy of BCG, maintenance treatment 
for 1-3 years was introduced and proven to be superior to an induction course 
alone118. Intravesical BCG-treatment is recommended as first line treatment in CIS 
and as adjuvant treatment in high-risk NMIBC by the EAU and the AUA12,123. In 
spite it being one of the most efficient immunological treatment for cancer, intra-
vesical BCG for bladder cancer is afflicted with a number of unsolved problems. 
One third of the patients, and even more in the high-risk group, do not respond 
to BCG treatment16. Side effects are common and severe in comparison to other 
intravesical agents23. For the non-responders, aside from causing unnecessary side 
effects, BCG treatment may delay other potentially curative treatments, such as 
radical cystectomy or radiotherapy17,124. Since the introduction of BCG for bladder 
cancer, much effort has been done to improve its efficacy and to find predictive 
markers for recurrence and progression following BCG treatment.
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As distinct from recurrence, there is still an uncertainty whether BCG reduces the 
risk of progression in NMIBC. In our present study we investigated the long-term 
effect of BCG on recurrence, progression and CSM, and in particular whether BCG 
treatment delays and prevents progression and CSM. In our study we showed that 
BCG reduce the rate of progression among patients with high risk NMIBC. This 
result is supported by a few relatively small, randomized  studies from the late 
1980’s and early 1990’s, of approximately 200 hundred patients with NMIBC, 
which showed that BCG reduced disease progression125,126. After the approval of 
BCG for NMIBC, randomized studies in which BCG-treatment was compared 
with no intravesical treatment at all have been difficult to perform for ethical 
reasons. Subsequent knowledge on the efficacy of BCG on progression was 
derived from prospective and retrospective cohort studies, or randomized studies 
in comparing BCG to other treatments. From these randomized studies there are 
conflicting results. In a meta-analysis from 2002, evaluating data from more than 
4800 patients, Sylvester et al demonstrate that BCG therapy prevents, or at least 
delays, the risk of tumor progression25. When compared to mutamycin for NMIBC, 
BCG did not result in decreased progression or disease specific survival in an 
individual patient data meta-analysis from 2009 of 9 randomized trials including 
2820 patients127. A recently published meta-analysis of randomized trials both on 
BCG vs. non-BCG and head-to-head trials on BCG vs. other intravesical agents 
(mutamycin, epirubicin, interferon) the authors conclude that BCG is superior to 
any other intravesical agent in decreasing progression122.
Non-randomized cohort studies, as our, reflect how BCG is used in practice but 
with confounding difficulties. As opposed to randomized studies patients tend not 
to be excluded due to age, gender, ethnicity or poor performance status. Many 
of these studies are characterized by heterogeneity of patient populations, a short 
follow-up period and a non-uniform definition of disease progression. In our pre-
sent study a fixed cohort was followed over a comparatively long time for well-
defined end-points. This study, among others shows positive progression effects 
from BCG treatment128.
Despite positive reduction effects in case progression, a well-defined cohort, a long 
follow-up and a high death rate, we could not show any statistically significant 
reduction of CSM in our study. Our finding is consistent with other research to date, 
as no randomized studies have shown a reduction of CSM in high-risk NMIBC 
after BCG treatment. In fact, there is scarce evidence that any of the intravesical 
agents currently used, BCG included, directly influence cancer specific survival 
(CSS) or overall survival (OS). One reason might be competing mortality among 
bladder cancer patients, who are at relatively high age at diagnosis, and have a 
higher comorbidity than expected129, probably due to common risk factors such 
as smoking. Prospective data in a number of studies show that OS is substantially 
lower in Ta-tumors and slightly lower in T1-tumors compared to CSS130.
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The reasons for BCG failure may lie in clinical factors predictive for recurrence 
(tumor multiplicity and prior recurrence rate) and progression (tumor stage and 
grade) after BCG. Similarly, the very prerequisites for BCG-treatment (direct 
contact between target and BCG, viable BCG and an intact immune system) and 
the mechanisms of action that lie herein, may too hold the answers.
5.2 The role of NO and NO forming cells in BCG 
treatment
Two of the studies underlying this thesis suggest a role for NO in BCG treatment of 
bladder cancer. Firstly, we have identified promoter and intragenic polymorphisms 
in NOS2 and NOS3 associated with outcomes after BCG treatment. Secondly, we 
have confirmed earlier findings that NO concentration is increased in the  bladder 
during BCG treatment and that macrophages stimulated with BCG express NOS2 
and NO. We have also been able to confirm that urothelial bladder cancer cells 
express NOS2 and NO. Unlike what has been shown in our earlier studies, expres-
sion of NOS2 and NO by bladder cancer cells depended on macrophage activation. 
The following sections will concern some aspects of these findings and possible 
future implications.
5.2.1 On the origin of NO
From previous research in our and other research-groups we know that bladder 
cancer, and especially CIS, is associated with an increased formation of NO85. 
We have also detected a significant increase in NO concentration during BCG 
treatment. Despite being a highly diffusible molecule, the range of action of NO 
from its point of origin does not exceed more than the amplitude of 10 cells63. NO 
detected in the bladder during and after BCG treatment might thus originate either 
from the tumor cells, the macrophages and/or other immunocytes or the urothelial 
cells in the bladder mucosa. 
Inflammatory pathways in BCG-patients are initiated by the activation of membrane-
bound receptors. The membrane-bound receptors TLR2, 4 and 9 that recognize 
BCG are present in both macrophages and normal urothelium131. Binding to these 
receptors results in an activation of NFkB, and a subsequent production of NOS2 
and NO55. Internalization of BCG is an important step for the macrophages to 
present or kill mycobacteria. Macrophages use NO in order to eliminate ingested 
mycobacteria89.
Urothelial cancer cells and normal urothelium are able to internalize BCG both 
in vivo and in vitro132. Based on a very limited number of studies there is some 
evidence that BCG-treatment results in NOS2-expression in urothelial cells in vivo. 
Immunohistochemical staining of the bladder mucosa showed that macrophages 
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and urothelial cells increased their formation of NOS2 after BCG treatment43,93. 
Immunohistochemical staining specifically for NOS2 in macrophages was only 
performed in one of these studies and indicated that NOS2 expression was higher 
in macrophages than in urothelial cells93. In vitro, there is until now only one 
study regarding NOS-expression by urothelial cells after BCG stimulation. In this 
study NOS expression was detected in primary culture of urothelial cells after the 
cell culture had been incubated with BCG94. Our study did not investigate NOS-
expression in normal urothelium. Instead in vitro testing was conducted on immor-
tally transformed urothelial cell lines. Most other in vitro studies of the impact 
of BCG on urothelium are performed in this way, and the results as compared to 
urothelial cells are equally difficult to interpret. 
Bladder cancer tumor cells have the potential to express NOS and form NO. NOS 
expression in bladder tissue from bladder cancer patients has been detected in both 
bladder tumor cells91,133 and in normal urothelium134. NO has also been detected at a 
higher concentration in the bladder of bladder cancer patients than in healthy controls. 
The increased formation correlated with the expression of NOS284. Altogether, there 
is convincing evidence that bladder tumor cells are able to express NOS2 and form 
NO. For obvious reasons the influence of BCG on bladder cancer cells in humans 
in vivo has not been studied. In a few in vitro murine studies however, there is some 
evidence that tumor cells are able to form NO upon stimulation with BCG alone, 
which is in direct contradiction to our study results94,135. One possible explanation 
for the discrepancy may be that in these two studies another strain of BCG (Tice) 
was used than in our study (RIVM). After decades of passaging the now available 
BCG strains differ from a genetic point, a fact that may influence their virulence136. 
Other cell types in the BCG reaction express and form NO upon activation. Upon 
e-coli infection of the mouse bladder, polymorphonuclear neutrophils (PMN) 
predominantly expresses NOS2137. PMNs have also been detected in the bladder 
wall after BCG instillation138. This cell type’s importance in the BCG-reaction in 
bladder cancer is underlined by the observation in murine in vivo experiments that 
depletion of neutrophils revokes the antitumor efficacy of BCG139. There has been 
no investigation of neutrophil expression of NOS2 after BCG treatment, but based 
on studies of other microbials such as E. coli, the involvement of NO in microbial 
killing by neutrophils most probably is of very little importance. Neutrophils do 
not use NO for killing, neither for microbials nor tumor cells, and there is little 
evidence that depletion of NOS2 impairs neutrophilic tumoricidal efficacy 140.
In summary, studies on tuberculosis have shown that macrophages are activated 
by mycobacteria and that macrophage action against BCG and other mycobacteria 
is mediated by nitric oxide. NOS2 has also been detected in macrophages in the 
bladder mucosa after BCG treatment. Our present study shows that macrophages 
express NOS2 and produce NO upon stimulation with BCG and that bladder  cancer 
cell formation of NO is dependent on macrophage-derived soluble factors. In 
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contrast to what has been shown in urothelial cells, there is convincing evidence 
that macrophages produce NO upon stimulation with BCG, a fact that indicates 
that macrophages might be the most important source of NO in the bladder during 
BCG treatment.
5.2.2 On the role of NOS polymorphisms in NO production
We hypothesized that NOS polymorphism would influence NOS activity and NO 
concentration in bladder cancer patients. Direct measurement of NO concentra-
tion and NOS activity was not performed in the patients in our study. We instead 
relied on several previous studies in which the current polymorphisms had been 
associated with altered enzyme activity. Polymorphisms in the promoter region 
of NOS2 ((CCTTT)n) and NOS3 (SNP -786T>C) had been associated with vari-
ations in expression of NOS2 and NOS3 respectively, as well as formation of 
NO110,111,120,141. Most of these studies concerned non-malignant diseases and until 
now there have been no specific studies on bladder cancer analysing the association 
between NOS polymorphism and NOS activity.
5.2.3 On the role of NO in BCG treatment and bladder cancer
In vitro studies on the direct effects of BCG alone on cultured bladder cells have 
shown both cytotoxic and cytostatic effects of BCG36,142. In our study (Paper I) 
there was no indication that BCG alone exerts a cytotoxic effect on bladder cancer 
cells. In vivo the roll of direct killing by BCG is contradicted by the observation 
that the host has to have an intact immune system for BCG to work. 
Therefore, most probably there are other factors that mediate the effect of BCG.
There are conflicting reports on the effect of NO on tumor cells. Whereas some 
studies show that NO enhances tumor growth and dissemination, others suggest a 
tumoricidal role for NO143-145. For bladder cancer several studies propose that some 
of the anti-tumor effect seen after BCG-treatment is actually mediated by NO86,96.
We have known for 30 years, at least in vitro, that NO is one of the effector mol-
ecules in macrophage-dependent tumor cytotoxicity. Already in 1989 Hibbs et al 
were able to show that NO caused the same pattern of cytotoxicity in hepatocytes 
as cytotoxic activated macrophages49. Although being an important player in the 
protection against mycobacteria, and despite convincing in vitro evidence, the 
specific role in vivo of macrophages and NO in BCG-treatment of bladder cancer 
has yet to be confirmed. 
Mycobacteria, the genus to which BCG belongs, are aerobic intracellular bacilli. 
They are normally taken up by macrophages, where they multiply and prosper by 
utilising the cell’s nutrients and evading being killed. BCG is an attenuated strain 
of Mycobacterium bovis and activates the immune system much the same way 
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as other mycobacteria. The immune response to BCG is both innate and adapted, 
the innate phase associated with activation of cell types such as granulocytes, 
monocytes and NK cells followed by a T-cell dependent adapted phase. The initial 
step involves activation of urothelial- and antigen-presenting cells, which produce 
chemokines (IL-8, MCP-1) and cytokines (IFNγ and TNFα)146 that then attract and 
activate neutrophils and macrophages. These cells reside in the bladder wall and 
give rise to the characteristic granulomas following intravesical BCG treatment. 
One feature of classically activated macrophages (M1) is an increased NOS2-
dependent formation of NO147. In activated macrophages, NO and reactive nitrogen 
intermediates (RNI) contributes to the elimination of phagocytized mycobacte-
ria148. Activated macrophages also act as antigen-presenting cells by presenting 
mycobacterial remnants in MHC2-complexes on their surface, thus activating 
T-cells in the adaptive immune response. A third role of activated macrophages 
is the formation of T-cell activating cytokines such as IL-2, IL-18 and IL-2397. 
BCG-activated macrophages exert their cytotoxicity either by direct effector-target 
cell contact or by the release of soluble factors149. The knowledge about contact 
induced cytotoxicity is scarce but might include apoptosis-inducing factors such 
as Fas-ligands and Tnf-Related Apoptosis Inducing Factor (TRAIL). Soluble 
factors have been estimated to account for 50 % of the total killing, and involves 
TNFα, IFNγ and NO150. 
Despite the in vitro evidence supporting NO-involvement in mycobacteria-
induced macrophage cytotoxicity, in our study BCG-induced cytotoxicity, exerted 
by soluble factors, did not involve NO. Our result is in line with the results of 
other studies98,151. In an in vitro study by Yamada et al from 2000, BCG-induced 
macrophage cytotoxicity against MBT-2 cells was enhanced rather than reduced 
when a NOS-inhibitor (L-NMMA) was added to the culture medium. The same 
study also indicated the importance of viable BCG, since cytotoxicity was only 
increased when living bacteria was used98. A reason for BCG failure might be 
that a high concentration of NO in the bladder kill viable BCG and thus decrease 
BCG mediated cytotoxicity.
The same study by Yamada et al, showed that BCG induced macrophage cytotox-
icity was highly dependent on soluble factors such as IFNγ and TNFα, cytokines 
that promote the cytotoxic activity of both the innate and the adaptive immune 
system. In our study we detected the expression in macrophages of a number of 
inflammatory genes in macrophages, among them IL6 and IL2, cytokines known 
to be involved in BCG induced cytotoxicity97. However, we did not detect expres-
sion of IFNγ and TNFα genes in our study. In contrast to Yamada et al we did not 
perform analyses on the actual presence of cytokines in the supernatant. Time 
may be another influencing factor, as cytokines are expressed in a time dependent 
manner. Following the first BCG instillation, the first cytokines to appear in the 
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urine are IL1, IL6, IL8 and IL10. IFNγ and TNFα have been detected only later 
during BCG treatment146. Yamada analyzed the supernatant from BCG stimulated 
macrophages after 36 hours, whereas our analyses were performed after 24 hours. 
This may explain why expression of these genes was not detected in our study.
The proximity of macrophages to their target might be an important factor in vivo. 
In CIS cases, macrophages existing in a high density close to the tumor cells are 
associated with reduced recurrence free survival time, whereas macrophages 
located beyond the lamina propria do not seem to affect this152. As NO is a mol-
ecule with a short half-life its effect decreases proportionate with distance. The 
concentration needed to exert cytotoxicity has been reported to be >200 nM153, 
which therefore requires close proximity between the macrophage and the target 
cell in order to exert an effect. Our previous studies showed that macrophages in 
the bladder wall express NOS2 upon stimulation with BCG93. We detected these 
activated macrophages in randomly taken biopsies of the bladder wall and still 
do not know whether they are also present in the peritumoral tissue, and thereby 
are able to exert cytotoxicity through the action of NO.
Comparative changes in NO concentration in the bladder before and during BCG 
treatment might reflect the distribution of different types of macrophages. Recent 
studies on the role of macrophages in bladder cancer have focused on tumor-
associated macrophages (TAM), and as a pre-BCG predictive markers based on 
their presence and density154. Bladder tumors, as most solid tumors, have a high 
density of tumor-associated macrophages surrounding the tumor cells155 and they 
appear in two phenotypes, M1 or M2. While the M1 phenotype is associated with 
tumor suppression and cytotoxicity, the M2 phenotype is associated with tumor 
progression and immune suppression60. The interplay between these macrophages 
and tumor cells is crucial for survival and dissemination of the tumor. The cancer 
cell has a number of strategies to evade immune destruction, among them the 
 ability to recruit and polarize macrophages into the M2 phenotype156. In a number 
of studies, high density of TAM was associated with reduced recurrence- and pro-
gression free survival after BCG treatment39,157. This process includes an increased 
concentration of TGFβ. Among many effects, TGFβ down-regulates NFκB, a 
well-known transcription factor for NOS2, and thus transforms M1 into M2158. 
An activated M1 macrophage produces NOS2 and NO when activated and TAM 
expression of NOS2 is used to identify polarized M1 macrophages. An increased 
formation of NO during BCG treatment may thus reflect a M1/M2 ratio that pro-
motes tumor suppression and cytotoxicity, making NO an indicator of successful 
treatment rather than an effector molecule. 
Most cell types are able to express NOS2 and NO with the right stimulation. In 
vitro, a mixture of LPS and IFNγ evokes a cellular response characterized by the 
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formation of NO and a number of additional cytokines and chemokines86,159. As 
mentioned previously, there is both in vitro and in vivo evidence that BCG instil-
lation leads to urothelial NOS2 expression and NO formation94. In vivo experi-
ments on mice, show that in response to highly virulent invaders such as e-coli, 
urothelial cells are able to give rise to respond by producing NO and NOS2137. 
For less virulent bacterias, such as BCG, the reaction of the urothelium is prob-
ably less prominent. Whether NO formation and NOS expression in urothelial 
cells after BCG stimulation is an important effect in vivo in humans, however, 
still remains to be seen.
In summary, our study (Paper 1) suggests a role for macrophages in BCG induced 
cytotoxicity against bladder cancer cells. Based on in vitro and in vivo observa-
tions in other studies the increased NO formation during BCG treatment appears 
to have both negative and positive effects. 
5.2.4 On the role of NO in cancer and BCG failure
NO has a dual role in carcinogenesis and tumor progression that depends not 
only on concentration and the quantity produced, but also on the characteristics 
of the cells and tissue where NO is produced92. The cells of the growing tumor 
have tumorigenic properties through the action of NOS2, whereas the cells of the 
surrounding stromal cells such as macrophages, have NOS2-dependent tumori-
cidal activity74. Increased NO production in the bladder before and during BCG 
treatment might thus have divergent effects.
NOS2 expression has been detected in vivo in a number of tumors. In a few of these 
studies expression was associated with improved prognosis160,161, but in the major-
ity of the published papers NOS2 expression in different cancers was associated 
with impaired outcome in terms of recurrence, progression and CSM 162-164. In one 
bladder cancer study, tumor expression of NOS2 was associated with decreased 
recurrence free survival134. In another study, all of the few patients who expressed 
intratumoral NOS2 experienced recurrence, as opposed to the patients who did not43.
In addition to our investigations, there are a several studies indicating a role for 
NOS2 polymorphisms in cancer development165-167. In the present study long repeats 
of (CCTTT)n of the NOS2-promoter satellite were associated with BCG-failure in 
high-risk bladder cancer cases. Earlier studies have identified polymorphisms asso-
ciated with BCG-failure42, but so far there is only one other study that has studied 
BCG outcome related to NOS2 promoter polymorphisms and in this study no such 
association was seen168. However, this study differed from ours in regard to follow 
up (shorter), endpoint (recurrence only) and polymorphism (NOS2 -1026C/A).
There are conflicting results regarding the role of NOS3-polymorphisms in cancer 
development, with studies supporting both a tumor stimulating 169,170 and a tumor 
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suppressing effect of NOS3171,172. In our study the NOS3 genotype (c-allele of 
rs2070744) that presumably would result in a low expression of NOS3 and NO 
was associated with an increased cancer risk and BCG-failure. These results were 
supported by earlier observations in an in vitro study on a breast cancer cell line, 
MCF-7, which upon overexpression of NOS3 and NO was afflicted by increased 
apoptosis and impaired invasiveness. Another in vivo study on breast cancer patients 
had opposite results. In this study, the c-allele of rs2070744 was associated with 
less progression and improved survival. There was, however, no increased risk 
for breast cancer associated to the c-allele173.
In the famous article Hallmarks of cancer, from 2000 by Hanahan and Weinberg, 
a number of traits are listed that characterizes the transformation of a normal cell 
into a cancer cell. In the first update from 2011, another two traits (reprogramming 
of energy metabolism, evading immune destruction) were added to the original 
six (sustaining proliferative signalling, evading growth suppressors, resisting cell 
death, enabling replicative immortality, inducing angiogenesis, and activating 
invasion and metastasis)174. Among these traits there are several involving NO. 
In vitro cell culture experiments and murine in vivo studies have shown that an 
increased NO production by tumor cells results in decreased apoptosis, sustained 
angiogenesis145,175, increased tissue invasion and metastasis92, immune system 
evasion176,177 and increased tumor growth and proliferation144. In several of these 
studies, NO inhibitors were able to antagonize this development.
In a study by Mitropoulos et al, patients with bladder tumors expressing NOS2 
recurred after BCG, whereas the patients without intratumoral NOS2 did not43. 
In our study on polymorphisms the genotype associated with increased NOS2-
expression was associated with BCG failure. Earlier discoveries on how tumors 
evade immune destruction may offer an explanation. Lymphocytes, crucial for 
BCG mechanism of action, are affected by elevated concentration of NO with 
decreased proliferation and cytotoxicity176. A high concentration as we have detected 
(Paper I) in the bladder during BCG treatment might impair lymphocyte function 
and decrease the effect of BCG. Another possible explanation is that nitric oxide 
locally produced by tumor cells, have a similar effect. Another finding is that 
continuous elevated concentration of NO makes tumor cells resistant to higher 
concentrations, as during the BCG reaction, and thus deleterious effects of NO178,179. 
The dual role of NOS and NO in cancer may also depend on the cell type. In an 
murine in vivo study, inhibition of ovarian cancer cell proliferation was associ-
ated with activated NOS2 expressing macrophages180. Also endothelial cells seem 
to be of importance. In an in vitro study of malignant melanoma, endothelial cell 
derived NOS3-dependent NO formation had a cytotoxic effect on disseminating 
tumor cells181, a finding that might explain our result on BCG treatment and NOS3 
polymorphism, where the genotype associated with low NO formation was associ-
ated progression and CSM. 
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Inhibition of NO in patients with NOS2 expression or a genotype associated with 
high NOS2-expression might improve outcome in bladder cancer after BCG-
treatment. In fact, murine studies have indicated that orally ingested or intratumoral 
delivery of NOS-inhibitors had favourable effect on outcome in bladder cancer 
after BCG treatment92,151. So far NOS-inhibitors have not been used clinically 
in the treatment of bladder cancer or cancer in general. A clinical trial, where a 
NOS2 inhibitor was combined with docetaxel for advanced solid non-hematologic 
malignancies, showed no reduction of tumor growth compared to docetaxel alone, 
and increased side effects182. 
Until recently there was no other immune-modulating therapy in bladder cancer 
than BCG. During the last few years, however, there has been a considerable develop-
ment in cancer therapy targeting immunological mechanisms. In  bladder cancer, 
immune checkpoint inhibitors have been approved for treatment of advanced MIBC 
with metastasis. In a recent study of NMIBC patients, PD-L1 was increased after 
BCG treatment in both tumor cells and tumor infiltrating inflammatory cells after 
BCG-treatment183. PD-L1-inhibitors have also been tested in combination with BCG 
with promising results in an orthotopic rat bladder cancer model184. Considering 
the suppressing effect of NO on immune cells, a combination of NOS2 inhibitors 
with immune checkpoint blockade may be an option in NOS2-expressing tumors. 
This combination is actually under current evaluation in patients with malignant 
melanoma in an on going study, however no results have been published yet182. 
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6 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES
From the studies of this thesis we concluded that BCG is an effective treatment 
in NMIBC regarding both recurrence and progression. However, recurrence- and 
progression rates (40 and 25 % respectively) were still considerable. Analysis of 
NOS2 and NOS3 polymorphisms might be a method to identify non-responders, 
and offer them alternative treatment at an early stage. The mechanism behind the 
NOS polymorphism influence on bladder cancer and BCG remains unclear, but 
might involve increased NOS2 activity and decreased NOS3 activity. Although 
there are a number of studies that suggest macrophage involvement in NOS-
dependent cytotoxicity against cancer cells both in vivo and in vitro, our study did 
not  support this hypothesis. However, our study suggests a roll for macrophages 
in BCG induced cytotoxicity against bladder cancer cells.
In comparing the cohort and randomized studies used in Papers II and III, several 
limitations have come to light. Specific data on BCG maintenance, rate of second 
look procedures, concurrent smoking status, and NOS2 and NOS3 protein and 
mRNA measurements in polymorphism, are lacking. On the other hand, recognized 
strengths in the studies were: the long follow-up, the fixed cohort and the low 
number of patients who were lost to follow-up, the quality of the initial TUR-BT 
(detrusor muscle in 83% of the T1 tumors) and the uniform pathologic assessment.
Planned prospective studies include detection of NOS expression in bladder tumors 
in NMIBC patients concurrently with NOS polymorphism analysis in order to 
detect the association between NOS expression, NOS polymorphism and BCG 
efficacy. For tumors with increased NOS2 expression, NO inhibitors that specifi-
cally target the tumor cells may be an efficient adjuvant to BCG. To my  knowledge 
to date, there is no such pharmacological agent yet, and the development of hom-
ing NOS-inhibitors for use in vivo may be an interesting and efficacious area of 
future research. Prospective research could also focus on macrophage differentia-
tion, the associations between NOS polymorphism and peritumoral M1 polarized 
macrophages and their subsequent impact on intravesical NO production, and 
outcomes after BCG treatment.
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